Treatment of Respiratory Syncytial Virus Bronchiolitis in Young Infants With Humanized Monoclonal Antibody: A Randomized Clinical Trial (Palivizumab Study)
Phase of Trial: Phase III
Latest Information Update: 13 Sep 2016
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- 28 Aug 2016 Planned number of patients changed from 200 to 420.
- 28 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018.
- 28 Aug 2016 Planned primary completion date changed from 1 Apr 2016 to 1 May 2018.